Evidence map›Paper›PMID 28396837›Full record

ArticleFEBS open bio2017

Myostatin promotes tenogenic differentiation of C2C12 myoblast cells through Smad3.

Kazutaka Uemura, Masanori Hayashi, Toshiro Itsubo, Ayumu Oishi, Hiroko Iwakawa, Masatoshi Komatsu, Shigeharu Uchiyama, Hiroyuki Kato

Open access · goldAbstract read
In one paragraph

Article in FEBS open bio, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.3field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Effects of Myostatin on Nuclear Morphology at the Myotendinous Junction.International journal of molecular sciences · 2023
    Article
  6. Review
  7. Review
  8. Factors Involved in Morphogenesis in the Muscle-Tendon-Bone Complex.International journal of molecular sciences · 2021
    Review
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Kazutaka UemuraDepartment of Orthopaedic Surgery Shinshu University School of Medicine Matsumoto Japan.
Masanori HayashiDepartment of Orthopaedic Surgery Shinshu University School of Medicine Matsumoto Japan.
Toshiro ItsuboSports Medicine Center Aizawa Hospital Matsumoto Japan.
Ayumu OishiDepartment of Orthopaedic Surgery Shinshu University School of Medicine Matsumoto Japan.
Hiroko IwakawaDepartment of Orthopaedic Surgery Shinshu University School of Medicine Matsumoto Japan.
Masatoshi KomatsuDepartment of Orthopaedic Surgery Shinshu University School of Medicine Matsumoto Japan.
Shigeharu UchiyamaDepartment of Orthopaedic Surgery Shinshu University School of Medicine Matsumoto Japan.
Hiroyuki KatoDepartment of Orthopaedic Surgery Shinshu University School of Medicine Matsumoto Japan.
Shinshu University · JPAizawa Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myostatin, a member of the transforming growth factor-β (TGF-β) superfamily, is expressed in developing and adult skeletal muscle and negatively regulates skeletal muscle growth. Recently, myostatin has been found to be expressed in tendons and increases tendon fibroblast proliferation and the expression of tenocyte markers. C2C12 is a mouse myoblast cell line, which has the ability to transdifferentiate into osteoblast and adipocyte lineages. We hypothesized that myostatin is capable of inducing tenogenic differentiation of C2C12 cells. We found that the expression of scleraxis, a tendon progenitor cell marker, is much higher in C2C12 than in the multipotent mouse mesenchymal fibroblast cell line C3H10T1/2. In comparison with other growth factors, myostatin significantly up-regulated the expression of the tenogenic marker in C2C12 cells under serum-free culture conditions. Immunohistochemistry showed that myostatin inhibited myotube formation and promoted the formation of spindle-shaped cells expressing tenomodulin. We examined signaling pathways essential for tenogenic differentiation to clarify the mechanism of myostatin-induced differentiation of C2C12 into tenocytes. The expression of tenomodulin was significantly suppressed by treatment with the ALK inhibitor SB341542, in contrast to p38MAPK (SB203580) and MEK1 (PD98059) inhibitors. RNAi silencing of Smad3 significantly suppressed myostatin-induced tenomodulin expression. These results indicate that myostatin has a potential role in the induction of tenogenic differentiation of C2C12 cells, which have tendon progenitor cell characteristics, through activation of Smad3-mediated signaling.

Indexed as

C2C12myostatinSmad3tenocytetenomodulin

Identifiers

PMID28396837
PMCPMC5377394
OpenAlexW2583439008

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.